Osteoarthritis in cats: does gabapentin improve mobility and pain scores? — POSSIBLE

In cats with osteoarthritis, does gabapentin vs placebo improve mobility and pain scores?

Shelf #742 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE: The only placebo-controlled trial on this question is a single blinded randomised crossover study in 20 geriatric osteoarthritic cats (Guedes 2018). On gabapentin 10 mg/kg twice daily, owners' client-specific outcome measure (CSOM) ratings had approximately 3-fold greater odds of indicating improvement in the activities each cat was impaired in, versus placebo — a relative (odds) measure, and the record gives no absolute responder proportions alongside it. Against that owner-perceived benefit, objectively measured activity was significantly LOWER on gabapentin than on placebo (mean daily activity counts 39,038 versus 48,333), and adverse events were far commoner on gabapentin (10 cats, mostly sedation, ataxia, weakness and muscle tremors) than on placebo (1 cat, lethargy). More cats deteriorated after crossing from gabapentin to placebo than after the opposite switch, which supports a real perceived effect, but the pattern — owners see better mobility while accelerometers see a quieter, more sedated cat — is exactly why the stamp stops at POSSIBLE. Design class (a): randomisation and blinding are both established by the carded record's own wording ('Blinded, placebo-controlled, randomized crossover-design study'). The honest limits: one small trial, 2 weeks per treatment period with no washout between periods (carryover cannot be excluded), geriatric cats aged 10 years or older only, and the benefit measure is owner perception under blinding while the objective activity measure moved the other way. Distinct from Shelf #304 (a single pre-visit gabapentin dose for transport/visit stress in cats) — a different question, and neither of #304's claim-carriers (PMID: 29099247; PMID: 35481442) is re-carded here. Drafted Nov 10, 2026 (VetMed build, topic #742); all figures from the abstract fetched and verified at drafting.

Guedes 2018: in 20 osteoarthritic geriatric cats, gabapentin gave approximately 3-fold greater odds of owner-rated improvement in impaired activities vs placebo — but activity counts were significantly lower on gabapentin (39,038 vs 48,333 counts/day) and sedation was common

Blinded, placebo-controlled, randomised crossover study (record's own wording: 'Blinded, placebo-controlled, randomized crossover-design study'; publication types include Randomized Controlled Trial, Veterinary)

Who: Cats: 20 osteoarthritic cats aged 10 years or older (geriatric). In a crossover design, cats received gabapentin 10 mg/kg (4.5 mg/lb) or placebo, orally, every 12 hours for 2 weeks, followed by the alternate treatment with no washout period. Activity was assessed with a collar-mounted accelerometer; owners completed a client-specific outcome measure (CSOM) questionnaire weekly covering 3 selected activities in which their own cat had impaired mobility, and gave quality-of-life (QOL) ratings at the end of the investigation.

Result: Gabapentin administration was associated with significantly greater odds (approximately 3-fold change — a relative odds measure; the record gives no absolute responder proportions) of CSOM ratings indicating improvement in impaired activities, compared with placebo. It was also associated with significantly lower mean daily activity counts (48,333 vs 39,038 counts/d as printed in the record, with the record stating the gabapentin counts were the lower ones). A greater proportion of cats had deterioration in impaired activities after crossover from gabapentin to placebo than when the opposite occurred, but the proportion of cats with worsened QOL did not differ between sequences. Adverse events were noted for 10 cats (9 that completed the study) during gabapentin treatment — sedation, ataxia, weakness and muscle tremors — and for 1 cat during placebo treatment (lethargy). The authors conclude gabapentin was associated with improvement in owner-identified impaired activities, that activity levels were lower than during placebo, and that sedation was the most common adverse effect.

Watch out: The two outcome families disagree: blinded owners perceived better mobility while the accelerometer recorded significantly less activity — consistent with a sedated cat being scored as more comfortable, or with genuine analgesia reducing restless movement; this record cannot separate those readings. There was no washout period between the 2-week treatment periods, so carryover effects cannot be excluded, and the population is geriatric cats (10 years or older) over short periods only. The 'Humans' MeSH term on this record is the record's own indexing and is reproduced as printed.

Guedes AGP, Meadows JM, Pypendop BH, Johnson EG, Zaffarano B. Assessment of the effects of gabapentin on activity levels and owner-perceived mobility impairment and quality of life in osteoarthritic geriatric cats. J Am Vet Med Assoc. 2018;253(5):579-585. PMID: 30110208. Registry ID: none in the record. MeSH: Animals · Cats · Female · Humans · Male · Anti-Inflammatory Agents, Non-Steroidal*/therapeutic use · Cat Diseases*/drug therapy, psychology · Cross-Over Studies · Double-Blind Method · Gabapentin*/therapeutic use · Geriatrics · Osteoarthritis*/drug therapy, veterinary · Ownership · Quality of Life · Surveys and Questionnaires · Treatment Outcome

Synthesis: one small blinded crossover trial — owners perceived better mobility on gabapentin while measured activity fell and sedation was common — POSSIBLE

Synthesis

Who: Synthesis of the card above: Guedes 2018 (20 osteoarthritic cats aged 10 years or older; blinded, placebo-controlled, randomised crossover; gabapentin 10 mg/kg orally every 12 hours, 2 weeks per period, no washout). No other PubMed record testing gabapentin against placebo for feline osteoarthritis pain or mobility was found at drafting — the remaining gabapentin-in-cats literature retrieved addressed pharmacokinetics, prescribing surveys or case reports, none of which can carry an efficacy claim for this question.

Result: (1) Owner-perceived mobility: approximately 3-fold greater odds (relative) of CSOM improvement ratings on gabapentin versus placebo, and more deterioration after switching gabapentin→placebo than placebo→gabapentin. (2) Objective activity: significantly lower mean daily activity counts on gabapentin (39,038 versus 48,333 counts/day). (3) Quality of life: no difference between sequences in the proportion of cats with worsened QOL. (4) Harms: adverse events in 10 cats on gabapentin (sedation most prominent) versus 1 cat on placebo.

Watch out: A one-trial shelf resting on 20 cats: it supports gabapentin as a possible help for owner-perceived mobility impairment in geriatric osteoarthritic cats, dosed twice daily, with sedation expected — it does not establish an analgesic effect separable from sedation, says nothing about younger cats, longer treatment, or objective gait improvement, and should not be read alongside Shelf #304 (pre-visit gabapentin for stress) as if the two were one evidence base: different question, different dosing, different records.

Synthesis of Guedes AGP et al. PMID: 30110208. Registry ID as on the individual card.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.